Home Blog Page 1867

Hong Kong’s RegTech-Driven Regulation Sets a Global Benchmark — KuCoin CEO BC Wong Highlights Hong Kong’s Credible Model for Global Digital Finance at FinTech Week

By
Advertorial Desk
-

HONG KONG, Nov. 5, 2025 /PRNewswire/ — At the “Regulator and Visionary Forum” on the main stage of Hong Kong FinTech Week 2025, BC Wong, Chief Executive Officer of KuCoin, a leading global crypto platform, acknowledged Hong Kong’s RegTech-driven and forward-looking approach to digital finance regulation, calling it a credible model for sustainable growth in the global digital finance ecosystem.

During the main stage panel discussion titled “The Globalization of Digital Asset Trading: Building a Borderless Financial Ecosystem,”  BC said: “The Hong Kong Securities and Futures Commission (SFC) has pioneered a RegTech-driven, science-based approach to regulation. This not only enhances market safety and transparency but also provides a clear framework for industry development.”


He further emphasized that maintaining consistent compliance is the cornerstone of long-term trust: “Platforms must ensure full and transparent disclosure to regulators. We cannot claim compliance in words but act otherwise. Trust comes from transparency, consistency, and accountability,” said BC.

BC added that KuCoin positions itself as a Web3 financial infrastructure, not merely an exchange. The company currently employs 1,300 staff, with over 80% being engineers, reflecting its technology and security driven foundation.

He noted that this dual focus on technology and compliance enables KuCoin to uphold the highest standards of safety and transparency, earning the trust of users and regulators worldwide. BC also highlighted that Hong Kong’s RegTech leadership reinforces KuCoin’s core belief: “A truly trusted exchange must be reliable to users, to regulators, and to its employees — and must uphold consistent standards across all jurisdictions.”

He concluded that KuCoin will continue engaging with regulators globally, including those in Hong Kong, to advance a balanced development of compliance, security, and innovation, contributing to a safe, transparent, and trustworthy global digital finance ecosystem.

About KuCoin

Founded in 2017, KuCoin is a leading global crypto platform built on trust, serving over 40 million users across 200+ countries and regions. With established recognition for its reliability, the platform leverages cutting-edge blockchain technology, robust liquidity solutions, and advanced user account protections to deliver a secure trading environment. KuCoin offers access to 1,000+ digital assets and solutions including Web3 wallet, Spot and Futures trading, institutional services, and payments. Recognized by Forbes as one of the “Best Crypto Apps & Exchanges” and a “Top 50 Global Unicorn” by Hurun, KuCoin holds SOC 2 Type II and ISO 27001:2022 certifications and is committed to security, compliance, and innovation under the leadership of CEO BC Wong.

Learn more: https://www.kucoin.com/

HeyMax Launches in Hong Kong and Announces Partnership with Cathay

By
Advertorial Desk
-

The Singapore-based loyalty platform builds on its July acquisition of Hong Kong fintech krip, partnering with Cathay as part of its strategy to scale its regional rewards ecosystem and expand partner and user growth.


SINGAPORE and HONG KONG SAR – Media OutReach Newswire – 5 November 2025 – HeyMax, the Singapore-based loyalty and travel rewards platform, today announced its launch into the Hong Kong market, marking its first international expansion and a new partnership with Cathay.

The move underscores HeyMax’s ambition to build Asia’s leading open loyalty ecosystem, enabling users to earn and redeem miles across multiple brands and partners. The company also plans to quadruple its team and expand regional partnerships to support this growth.

“As one of the world’s leading travel hubs, Hong Kong plays a pivotal role in connecting global travellers,” said Joe Lu, CEO and Co-founder of HeyMax. With both strong outbound and inbound demand, it’s a key market in building our global traveller network. HeyMax is well-positioned to help consumers turn everyday spending into meaningful travel experiences, while enabling businesses in Hong Kong to tap into the travel economy as a powerful way to engage their customers and members.”

Users in Hong Kong can earn Max Miles from over 300 leading merchants including Watsons, Trip.com, Klook, Starbucks, foodpanda and redeem them for flights, hotels, and rewards from over 30 programs, including Cathay, ALL Accor, and Qatar Airways. These partnerships reflect HeyMax’s role in connecting financial, lifestyle, and travel partners through a unified rewards platform that helps businesses drive deeper loyalty and unlock new value for consumers.

As part of the launch, starting today Cathay members in Hong Kong and Southeast Asia* can convert Max Miles into Asia Miles and redeem them for travel and lifestyle rewards, including flights on Cathay Pacific, partner airlines, and over 800 partners worldwide.

“As a premium travel lifestyle brand, partnering with HeyMax enables us to further strengthen our lifestyle ecosystem beyond our home hub of Hong Kong, giving our community of travellers across Southeast Asia more ways to turn everyday spending into meaningful travel experiences,” said Jonathan Ng, Cathay Regional Head of Customer Travel & Lifestyle for Southeast Asia and Oceania. “This partnership reflects our ongoing commitment to delivering greater flexibility, value, and choice to our members, wherever they are in their travel journey.”

The partnership marks a major step in expanding HeyMax’s regional rewards ecosystem and driving new collaborations.

“Hong Kong is one of Asia’s most influential markets for travel, finance, and lifestyle, a natural fit for HeyMax’s next phase of growth,” said David B. Wang, General Manager of HeyMax Hong Kong and Global Head of Loyalty Partnerships. “Through close collaboration with our partners, we look to help brands connect more deeply with travelers via Max Miles and strengthen our growing network of airline and hotel partners.”

Beyond merchants, HeyMax is also working with major partners operating in Hong Kong and beyond such as MoneyHero, Octopus, Preferrd and Visa, who are integrating Max Miles as part of their rewards and customer engagement strategies.

In addition, HeyMax’s FlyAnywhere feature lets users redeem Max Miles for any flight, on any airline, anywhere in the world. In addition to travel rewards, users can earn miles when purchasing digital vouchers from local favourites such as HKTVmall, 7-Eleven, JHC, and Starbucks, or when shopping for select lifestyle products.

The launch comes as Hong Kong continues to attract fintech and travel-tech companies seeking to serve a growing base of regional consumers.

“We welcome HeyMax’s decision to expand in Hong Kong,” said Jayne Chan, Head of Startups at InvestHK. “HeyMax’s expansion into Hong Kong underscores the city’s status as one of the region’s most vibrant startup hubs, with strong technology-powered customer engagement that supports continued growth in the travel and loyalty sectors.”

HeyMax aims to reach one million users and issue more than 2 billion Max Miles regionally by the end of 2026. The company continues to expand across financial services, insurance, F&B, and lifestyle sectors, following fivefold year-on-year revenue growth and an annualized revenue run rate of US$6 million reported in May.

*Applicable to members in Singapore, Malaysia, Indonesia, Thailand, the Philippines, and Vietnam.
Hashtag: #HeyMax

The issuer is solely responsible for the content of this announcement.

About HeyMax

HeyMax is a leading loyalty and travel rewards platform that turns everyday spending into meaningful travel, based in Singapore. HeyMax is on a mission to bring more joy and empathy to the world through travel. Its vision is to make travel more accessible and rewarding for everyone by turning the things you already do into free trips, year after year.

Users earn Max Miles from over 500 top merchants and redeem them directly for over 30 flights, hotels, and rewards programs, or use them for gift cards. Max Miles never expire, come with no fees, and offer unmatched flexibility for modern travelers.

HeyMax is backed by leading investors, including January Capital, Monk’s Hill Ventures, Tenity, Ascend Angels, and XA Network. For more information, please visit www.heymax.ai.

Wuxi Strikes a Historic Note as UNESCO “City of Music”

By
Advertorial Desk
-

BEIJING, CHINA – Media OutReach Newswire – 5 November 2025 – With its recent inclusion in the UNESCO Creative Cities Network as China’s first “World City of Music,” Wuxi is stepping confidently into a new chapter where culture, heritage, and innovation harmonize to shape a global cultural profile.

The Wuxi Symphony Orchestra at Yuantouzhu
The Wuxi Symphony Orchestra at Yuantouzhu

The recognition adds Wuxi to a prestigious roster of 76 music cities worldwide, such as Vienna, Liverpool, and Havana, marking a milestone not only for the city but also for China’s contemporary cultural landscape.

Long celebrated as the “Hometown of Chinese Folk Music,” Wuxi is the birthplace of renowned musician A Bing (Hua Yanjun) and his poetic masterpiece Erquan Yingyue (Moon Reflected on Second Spring). This emotionally profound composition continues to resonate across generations—its resonance once prompting conductor Seiji Ozawa to say that one should “listen kneeling” to fully honor its depth. Among China’s top ten erhu classics, eight originated in Wuxi, echoing the city’s deep musical roots.

Garden Music Concert in Wuxi
Garden Music Concert in Wuxi

Yet Wuxi today is not just looking back—it is accelerating forward. The Wuxi Symphony Orchestra, established in 2023, has quickly assembled world-class talent and embarked on tours across China and abroad, performing in cultural centers from Shanghai to Lisbon, London, and Tokyo. The new Wuxi Symphony Concert Hall, set to open on January 1, 2026, will serve as a flagship venue for international musical exchange.

Cultural continuity is another hallmark of the city. The Tianyun Society Kunqu salon has thrived for more than 400 years, while the “Nightingale” Youth Arts Program has nurtured artistic talent for over four decades. Wuxi’s music industry is robust and diverse, spanning 370 music companies, 2,079 training institutions, and a creative industry valued at nearly USD 1 billion annually. The city is also a global center for instrument craftsmanship, producing 50,000 erhu each year alongside harmonicas, accordions, and harps.

Wuxi’s musical story has always been global. From Yang Yinliu, who bridged Christian and Chinese musical traditions, to Gu Yuxiu, who translated Beethoven’s Ode to Joy and helped found China’s national symphony and conservatory institutions, the city has long served as a bridge between East and West.

Widely known as the “Pearl of Taihu Lake” and located just 30 minutes from Shanghai, Wuxi is recognized for its economic vitality, with a 2024 GDP of RMB 1.63 trillion. Today, its musical vision is expanding that identity—turning industry into artistry, heritage into contemporary creativity, and local culture into global resonance.

Wuxi’s designation as a UNESCO City of Music is not merely an honor—it is a new overture. What comes next may be even more compelling than the title itself.

Hashtag: #Wuxi

The issuer is solely responsible for the content of this announcement.

Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025

By
Advertorial Desk
-

-Positive data from Phase Ib study of ASC30 oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction; safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs) across all multiple ascending dose (MAD) cohorts.

-Phase Ib study data of ASC30 subcutaneous (SQ) injection showed that observed half-life reached 46 days for the treatment formulation (Injection A) and 75 days for the maintenance formulation (Injection B).

-Combination of ASC47 and ASC31, a novel peptide agonist targeting both GLP-1R and GIPR, significantly outperformed both tirzepatide and ASC31 monotherapy in promoting weight loss, body fat loss, and muscle preservation in diet-induced obesity (DIO) mouse studies.

-Presentations further highlight the promising efficacy and safety profiles of Ascletis’ diverse obesity pipeline and validate its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies.

HONG KONG, Nov. 5, 2025 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces multiple poster presentations of the full analysis of the Phase Ib study of ASC30 once-daily oral tablet, Phase Ib study of ASC30 once-monthly injection, and preclinical study of the combination of ASC31 and ASC47 at ObesityWeek® 2025 in Atlanta, Georgia.

Abstract Title: A full analysis of 28-Day MAD Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for obesity

Results:

Efficacy: Body weight changes from baseline were 6.3% reduction (multiple ascending dose (MAD) 2, n=8, 40 mg), 4.3% reduction (MAD 1, n=7, 20 mg), and 0.2% increase (placebo, n=6). No plateau was observed at Day 29. Body weight change from baseline was 4.8% reduction for MAD 3 (n=7, 60 mg), with the maximum body weight change being 9.3% reduction in this cohort. Excluding two outliers, the mean body weight change from baseline was 5.9% reduction for MAD 3.

GI Tolerability: In the MAD study, MAD 1 (20 mg cohort) showed no vomiting, while MAD 2 (40 mg cohort) had events. Titrating from 2 mg to 5 mg did not cause vomiting in MAD 1, but titrating from 2 mg to 10 mg did result in vomiting in MAD 2. Compared with MAD 2, MAD 3 showed no increasing trend in severity or incidence of gastrointestinal (GI) adverse events (AEs), despite two discontinuations due to principal investigator’s decisions, and one discontinuation due to subject withdrawal.

Safety: No serious adverse events (SAEs) or Grade ≥ 3 AEs, including GI events, were observed. Labs, vitals, ECGs (QTc), and physical exams were normal. No hepatic safety signals were detected across all MAD cohorts.

Conclusion: ASC30 once-daily oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction from baseline after 28-day treatment. The highest dose level (MAD 3, 60 mg) exhibited up to 9.3% body weight reduction, showed no increasing trend in severity or incidence in GI AEs. ASC30 was safe and well tolerated with only mild-to-moderate GI AEs across all MAD cohorts. The safety profile of ASC30 tablets was consistent with or better than that of the GLP-1R agonist class.

Abstract Title: ASC30, a Once-Monthly SQ Injected Small Molecule GLP-1RA in Participants with Obesity: A Ph Ib Study

Results: The observed half-life (time for ASC30 concentrations to reduce to fifty percent (50%) of ASC30’s Cmax) reached 46 days and 75 days, for ASC30 subcutaneous (SQ) treatment formulation (Injection A) and ASC30 SQ maintenance formulation (Injection B), respectively. Cmax-to-Cday29 ratio of 1.5:1, supports ASC30 SQ treatment formulation monthly dosing, while Cmax-to-Cday85 ratio of 2.5:1, supports ASC30 SQ maintenance formulation quarterly dosing.

No SAEs or Grade ≥ 3 AEs were observed. GI-related AEs were mild to moderate. Labs, vitals, ECGs (QTc), and physical exams were normal. No hepatic safety signals were detected across all cohorts.

Conclusion: ASC30 ultra-long-acting, slow-release SQ depot formulations demonstrated 46-day observed half-life (treatment formulation) and 75-day observed half-life (maintenance formulation), supporting both once-monthly treatment and once-quarterly maintenance therapies.

ASC30 SQ formulations were well tolerated, with only mild-to-moderate treatment-emergent adverse events (TEAEs), comparable or superior to those observed with GLP-1R agonists. Developed with Ascletis’ Ultra-Long-Acting Platform (ULAP) technology, ASC30 treatment and maintenance formulations represent a potential breakthrough in chronic weight management by improving treatment convenience, adherence, and quality of life.

Abstract Title: GLP-1R/GIPR Peptide Agonist ASC31 + ASC47 Shows 119.6% More Weight Loss than Tirzepatide in DIO Mice

Results: The combination of ASC47 plus ASC31 resulted in a 44.8% reduction in weight compared to a 19.1% reduction for ASC31 monotherapy. This was a 134% greater reduction than ASC31 alone. The combination of ASC47 plus tirzepatide resulted in a 38.1% reduction in weight compared to a 20.4% reduction for tirzepatide alone. This was an 87% greater reduction in weight compared to tirzepatide alone. The mean greater reduction in weight of ASC31 in combination with ASC47 compared to ASC31 alone (134%) is statistically significantly higher than that of tirzepatide plus ASC47 compared to tirzepatide alone (87%).

Conclusion: The combination of ASC47 and ASC31 significantly outperformed both tirzepatide and ASC31 monotherapy in promoting weight loss, body fat loss, and muscle preservation. The combination of ASC47 with either ASC31 or tirzepatide restored the body composition of obese mice to the level of healthy non-obese mice. ASC31 is a dual GLP-1R and GIPR peptide agonist. ASC47 is a small molecule thyroid hormone receptor beta (THRβ)-selective agonist and was designed with unique and differentiated properties to enable targeted delivery to adipose tissue.

Detailed data presented at ObesityWeek® 2025 can be found at Ascletis’ website (link).

“These presentations highlight the exciting efficacy and safety profiles of our diverse obesity pipeline of both small molecules and peptides and validate our proprietary AISBDD and ULAP technologies,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. “As we advance clinical development of ASC30, ASC31, and ASC47, we remain focused on close discussion with strategic partners to ensure that Ascletis is best positioned to address the needs of patients with obesity globally.”

About ASC30

ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044 without patent extensions.

About ASC31

ASC31 is an in-house discovered and developed novel peptide agonist targeting both GLP-1R and GIPR, which demonstrated a favorable pharmacokinetic profile in non-human primates as well as promising in vitro activities and in vivo efficacy in the diet-induced obese (DIO) mice. ASC31 is part of Ascletis’ discovery efforts to apply its Ultra-Long-Acting Platform (ULAP) to in-house discovered novel subcutaneously (SQ) injectable peptides and oral peptides.

About ASC47

ASC47 is an adipose-targeted, once-monthly SQ injected THRβ-selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies, Ascletis has developed multiple drug candidates in-house, including its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK). For more information, please visit www.ascletis.com.

Contact：

Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com

Ascletis Pharma Inc. PR and IR teams
+86-181-0650-9129 (China)
pr@ascletis.com
ir@ascletis.com

 

Mölnlycke® establishes first wound care manufacturing site in China

By
Advertorial Desk
-

CHANGSHU, China and GOTHENBURG, Sweden, Nov. 5, 2025 /PRNewswire/ — Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, is celebrating the commencement of its new wound care manufacturing site in Changshu, China. This strategic investment marks a milestone in Mölnlycke’s growth journey and the beginning of localised manufacturing in one of the world’s fastest-growing MedTech markets.

Mölnlycke establishes first wound care manufacturing site in China, marked by a commencement ceremony in Changshu.
Mölnlycke establishes first wound care manufacturing site in China, marked by a commencement ceremony in Changshu.

“Our site in Changshu marks another step forward in Mölnlycke’s ambition to manufacture products closer to where they are sold. It reflects our glocal approach, combining global standards with local relevance, and reinforces our commitment to sustainable growth, supply chain resilience and faster delivery of life-changing wound care solutions to caregivers and patients in China,” says Zlatko Rihter, CEO of Mölnlycke.

The manufacturing site, spanning 10,000 m2, will be set up in accordance with Mölnlycke’s global standards and is expected to initiate production of Mölnlycke wound care products at the end of 2026/early 2027. This strategic move will help future-proof Mölnlycke’s growth in China, laying the foundation for future capacity expansion and local job creation.

“This investment brings us closer to our customers in China and reinforces our mission to free patients and caregivers from the burden of wounds, with locally produced, high-quality solutions,” adds Jakob Sonnenberg, VP Greater China & India Wound Care at Mölnlycke.

The Changshu site strengthens Mölnlycke’s position in Asia and aligns with China’s growing demand for advanced, locally manufactured healthcare solutions.

For more information, please contact:

Jamie Smith
Media Relations Manager
Email: jamie.smith@molnlycke.com
Phone: +46 (0)722-553573

About Mölnlycke 

Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com

 

Sherwin-Williams Debuts at the China International Import Expo

By
Advertorial Desk
-

Joining Forces to Advance Global Sustainability Attributes

SHANGHAI, Nov. 5, 2025 /PRNewswire/ — Sherwin-Williams, a global innovator in paint and coatings, makes its inaugural appearance at the China International Import Expo (CIIE hereafter). From November 5 to 10, the Company welcomes visitors to Booth 3C7-02 in Hall 3 at the National Exhibition and Convention Center (Shanghai) to explore its latest innovations in products and technologies with sustainability attributes.

Sherwin-Williams Debuts at the China International Import Expo
Sherwin-Williams Debuts at the China International Import Expo

As global environmental regulations tighten, the demand for low volatile organic compounds (VOCs hereafter) coatings continue to grow. Sherwin-Williams is responding with a comprehensive portfolio of waterborne, powder, high-solids, and bio-based solutions tailored to meet demand. At this year’s CIIE, Sherwin-Williams Asia unites its six business units to showcase advanced coating technologies and products with sustainability attributes for industrial manufacturing, transportation, energy, infrastructure, furniture, packaging, and more. These solutions aim to drive CO2 emissions reduction, improve operational efficiency, extend asset life, and accelerate the transition toward a low-carbon circular economy.

New Products and Technologies Debuting in China

Leveraging the CIIE platform, Sherwin-Williams will launch several new products and technologies in China.

  • Heat Flex AEB – An engineering-grade thermal insulation and anti-corrosion coating designed to eliminate corrosion under insulation. Unlike conventional mineral wool systems, AEB can be applied directly to steel surfaces at elevated temperatures, significantly reducing downtime. This advanced solution is ideally suited for tanks, pipelines, offshore platforms, and chemical and energy facilities.
  • OneCure™ Two-Coat One-Bake Powder Technology – This innovative process enables the topcoat powder to be applied directly over uncured base powder, eliminating separate baking and cooling steps. The technology delivers superior edge protection and enhanced corrosion resistance, making it an ideal solution for sectors such as construction machinery and transportation.
  • Powdura® EV Insulation Powder – Developed for the new energy sector, this advanced coating creates a dense insulating layer on battery surfaces, effectively shielding components from external environments. It meets prevailing insulation voltage standards and offers full customization to address diverse industry needs.
  • Duraspar® High Performance Series – Delivering exceptional C5H-level protection, this advanced solution enhances production efficiency through wet-on-wet application and low-viscosity formulations. With high solids, low VOCs content, and versatile application capabilities, it stands as an optimal choice for the energy and heavy equipment sectors.

Adding Value Through Multi-Dimensional Innovation

Sherwin-Williams remains committed to achieving balance between performance and environmental responsibility. In the field of circularity, the Powdura® ECO powder coating series incorporates recycled plastics, delivering performance that meets or exceeds industry standards. In health and safety, Sherwin-Williams also offers Non-BPA (Bisphenol A) can coatings and low-odor furniture finishes, providing consumers with safer and more responsible choices. In functional enhancement, advanced features such as self-cleaning and heat-reflective properties added to coating products help improve building energy efficiency, creating greater environmental value.

Deep Roots in China, Honoring Cultural Heritage

At this year’s CIIE, Sherwin-Williams not only presents its latest technological innovations but also unveils its first brand video paying tribute to China’s intangible cultural heritage – exploring the integration of traditional craftsmanship with modern coating technologies, underscoring respect for Chinese culture and a commitment to cross-boundary innovation.

In addition to on-site visits, audiences can also access the Sherwin-Williams booth virtually. Follow the official Sherwin-Williams WeChat account for timely updates and comprehensive information.

-End-

About Sherwin-Williams

Founded in 1866, The Sherwin-Williams Company (NYSE: SHW) is a global innovator in the manufacture, development, distribution and sale of paint, coatings and related products to professional, industrial, commercial and retail customers. With a workforce of over 64,000 employees, the Company operates in more than 120 countries. In 2024, the Company delivered annual net sales of about US$ 23.1 billion.

Entering Asia in 1930 and regionally headquartered in Shanghai, The Sherwin-Williams Company today runs businesses in most of the Asian countries, supplying coating solutions with industry-recognized brands such as Sherwin-Williams®, Valspar®, Aquaguard®, Ultra®, Debeer Refinish®, Fluropon®, WeatherXL® and many more for the construction, furniture, industrial, packaging and transportation markets, etc.

 

Angel Yeast starts Operating New 11,000-Ton Yeast Protein Production Line to Meet Global Demand for Sustainable Nutrition

By
Advertorial Desk
-

YICHANG, China, Nov. 5, 2025 /PRNewswire/ — Angel Yeast Co., Ltd. (SH600298) has officially started operations at its next-generation yeast protein production line at the Baiyang Biotechnology Park in Yichang, Hubei. The facility has an annual production capacity of 11,000 tons of high-purity yeast protein with a protein content exceeding 80%. This marks a key step in meeting growing global demand for sustainable protein, significantly enhancing the company’s global manufacturing footprint and reinforcing its leadership in the alternative protein and sustainable nutrition markets.


As protein innovation becomes a strategic priority across the food sector, leading food companies are integrating multi-functional protein solutions into their product portfolios. The industry publication Foodaily commented, “Beyond traditional animal and plant proteins, novel sources such as yeast protein are emerging rapidly, bringing fresh vitality to the market.” Angel Yeast’s scale-up aligns directly with this growing trend.

In 2025, the company’s yeast protein product, AngeoPro, received the iSEE “Annual Innovative Technology” and the FoodBev “Best Ingredient Innovation” awards for its exceptional performance. As an efficient and environmentally friendly novel protein, it is rich in complete amino acids and dietary fiber. Through ongoing technological refinement, AngeoPro achieves industry-leading purity and a clean taste profile free from off-notes. Its clean flavor allows for direct consumption or blending with whey and soy, making it suitable for a variety of multi-protein applications.

Unlike traditional animal or plant proteins, Angel Yeast’s yeast protein is produced using advanced bio-fermentation technology. This new line integrates state-of-the-art process control technologies, enabling full-process automation from fermentation, autolysis, separation, to drying, while establishing an intelligent, end-to-end production system encompassing raw materials, packaging and warehousing. The entire manufacturing process takes place within controlled fermentation tanks, making it independent of climate, season, or location. This enables stable, highly efficient year-round production and delivers a protein source that is both resource-efficient and sustainable. The facility currently outputs 11,000 tons per year with built-in expansion capacity to meet future market growth.

Li Ku, General Manager of Angel Yeast’s Protein Nutrition and Flavoring Technology Center, said, “As global priorities continue to shift toward health, nutrition and sustainability, we see unprecedented market potential for yeast protein.” Li added, “We will continue to accelerate production expansion to deliver more innovative, high-quality and dependable yeast protein solutions to customers and consumers worldwide and help drive a more sustainable future for the global food industry.”

Health In Tech Announces New Davos 2026 Panel: “First Ladies: Backing Women Who Build” Featuring Cherie Blair CBE, KC

By
Advertorial Desk
-

STUART, Fla., Nov. 5, 2025 /PRNewswire/ — Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, today announced an expansion of its agenda for the Independent InsurTech Summit to be held during World Economic Forum Week 2026 in Davos, Switzerland.

Following the previously announced CEO panel, “AI and Institutional Resistance: CEOs Driving Change in Legacy Sectors,” Health In Tech will host a second session titled “First Ladies: Backing Women Who Build.” The panel will spotlight global leaders advancing women’s entrepreneurship, leadership, and access to capital across industries, exploring how innovation, education, and technology can close gender gaps in business creation and economic opportunity. 

Cherie Blair CBE, KC, Founder of the Cherie Blair Foundation for Women and Co-Founder and Chair of Omnia Strategy LLP, will join as a featured speaker. A leading King’s Counsel with over 35 years of experience, Blair has dedicated her career to promoting equality, access to justice, and women’s economic empowerment. Through the Cherie Blair Foundation for Women, she has helped thousands of women in low- and middle-income countries start, sustain, and grow successful businesses. She was awarded a CBE in the 2013 New Year’s Honours List for services to women’s issues and to charities in the UK and overseas.

“Cherie Blair’s voice and vision represent the very essence of inclusive innovation,” said Tim Johnson, CEO of Health In Tech. “Her leadership in empowering women entrepreneurs reflects Health In Tech’s ongoing commitment to advancing inclusive and responsible innovation.”

Health In Tech’s presence at Davos underscores the company’s ongoing commitment to advancing ethical, compliant, and outcome-driven AI within the health and insurance sectors. The company’s initiatives, including AskTim, its AI benefits counselor, and HITChain, an emerging framework for secure data validation and audit transparency, reflect its focus on responsible innovation across the industry.

Attendance and Media Access:

Attendance at Health In Tech’s Davos sessions will be open to World Economic Forum participants and invited guests. A detailed agenda, speaker lineup, and livestream registration will be shared on the company’s official event landing page as programming continues to develop. Each session will feature audience Q&A and closing remarks, followed by a press photo opportunity.

Event Overview
Date: Tuesday, January 20, 2026
Time: 1:00 p.m. CET
Location: Promenade 89, Davos Platz
Hosted by: Health In Tech
Moderator: Dustin Plantholt, Chief AI & Marketing Officer

Use of Forward‑Looking Statements

Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Health In Tech’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech’s operations, results of operations, growth strategy and liquidity.

About Health In Tech

Health In Tech (Nasdaq: “HIT”) is an Insurtech platform company backed by third-party AI technology, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, and TPAs. Learn more at healthintech.com.

About the Cherie Blair Foundation for Women
The Cherie Blair Foundation for Women works to create a future where women everywhere enjoy equal economic opportunities so they can thrive. Together with partners, we support women around the world to start, sustain and grow successful businesses; and we advocate for fairer business environments so women are not constrained by gendered barriers.

Investor Contact

Investor Relations:
ir@healthintech.com

Event Contact

Davos 2026 HIT Independent InsurTech Summit Contact:
dkearns@healthintech.com 

 

1...1,8661,8671,868...6,419Page 1,867 of 6,419